BioWorld

Dec. 3, 2007

Fate Tempts VCs With Viable Stem Cell Business Model

Amid a flurry of stem cell news, Fate Therapeutics raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. (BioWorld Today) Read More

Panel: FDA's Science 'Weak'; Increased Funding Needed

New Discoveries May Aid HIV Prevention, Treatment

FDA Amendments Act - Detrimental To Advertising Prescription Drug

Financings Roundup

Other News To Note

Clinic Roundup

Appointments And Advancements

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...